This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/chebi/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/wikipedia/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/pharmgkb/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/drugbank/
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/iuphar/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/mesh/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00875/identifier/guide-to-pharmacology/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://www.drugs.com/international/
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00875
rdf:type
n5:Drug
n5:description
Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States.
n5:group
approved withdrawn
n5:halfLife
19 to 39 hours
n5:indication
For use in the treatment of schizophrenia and depression
owl:sameAs
n8:DB00875 n9:DB00875
dcterms:title
Flupentixol
adms:identifier
n11:968 n12:968 n13:DB00875 n15:D01044 n16:PA10268 n20:Flupenthixol n24:5121
n5:mechanismOfAction
Flupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS.
n5:synonym
Flupentixolo Flupentixolum Flupenthixole Flupentixol Flupenthixol
n5:toxicity
LD<sub>50</sub>=300 mk/kg (Oral in mice); LD<sub>50</sub>=791 mg/kg (Oral in rats); LD<sub>50</sub>=87 mk/kg (IV in mice); LD<sub>50</sub>=37 mg/kg (IV in rats)
n5:foodInteraction
Take with food to reduce irritation. Avoid alcohol.
n5:mixture
n21:271B5530-363D-11E5-9242-09173F13E4C5 n21:271B552E-363D-11E5-9242-09173F13E4C5 n21:271B552F-363D-11E5-9242-09173F13E4C5 n21:271B552C-363D-11E5-9242-09173F13E4C5 n21:271B552D-363D-11E5-9242-09173F13E4C5
n5:proteinBinding
Highly bound to plasma proteins (>95%)
n5:salt
n5:synthesisReference
Smith Kline & French Laboratories; British Patent 925,538; May 8, 1963. Craig, P.N. and Zirkle, C.L.; U.S. Patent 3,282,930; November 1, 1966; assigned to Smith Kline & French Laboratories.
n3:hasConcept
n4:M0008640
foaf:page
n19:flupentixol.html
n5:IUPAC-Name
n6:271B5539-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B553F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B553E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B553B-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B553C-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B553D-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5537-363D-11E5-9242-09173F13E4C5 n6:271B554F-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5538-363D-11E5-9242-09173F13E4C5 n6:271B5535-363D-11E5-9242-09173F13E4C5 n6:271B5550-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5536-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:N05AF01
n5:H-Bond-Acceptor-Count
n6:271B5545-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5546-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5540-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5541-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5543-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5542-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5544-363D-11E5-9242-09173F13E4C5
n5:absorption
Fairly slow and incomplete after oral administration
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
2709-56-0
n5:category
n5:containedIn
n17:271B5533-363D-11E5-9242-09173F13E4C5 n17:271B5534-363D-11E5-9242-09173F13E4C5 n17:271B5531-363D-11E5-9242-09173F13E4C5 n17:271B5532-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B554B-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B554D-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B554E-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B554A-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5549-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B554C-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B553A-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5547-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5548-363D-11E5-9242-09173F13E4C5